[ {
  "@graph" : [ {
    "@id" : "http://www.tkuhn.ch/bel2nanopub/RAQfV5-xLlpw3kxtvQ4VjUdtLbOMXTLLzcIv2KILNHN2Q",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://www.tkuhn.ch/bel2nanopub/RAQfV5-xLlpw3kxtvQ4VjUdtLbOMXTLLzcIv2KILNHN2Q#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://www.tkuhn.ch/bel2nanopub/RAQfV5-xLlpw3kxtvQ4VjUdtLbOMXTLLzcIv2KILNHN2Q#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://www.tkuhn.ch/bel2nanopub/RAQfV5-xLlpw3kxtvQ4VjUdtLbOMXTLLzcIv2KILNHN2Q#pubinfo"
    } ]
  } ],
  "@id" : "http://www.tkuhn.ch/bel2nanopub/RAQfV5-xLlpw3kxtvQ4VjUdtLbOMXTLLzcIv2KILNHN2Q#Head"
}, {
  "@graph" : [ {
    "@id" : "http://www.tkuhn.ch/bel2nanopub/RAQfV5-xLlpw3kxtvQ4VjUdtLbOMXTLLzcIv2KILNHN2Q#_1",
    "@type" : [ "http://www.ebi.ac.uk/ontology-lookup/?termId=MOD:00000", "http://www.ebi.ac.uk/ontology-lookup/?termId=MOD:00696" ],
    "http://www.selventa.com/vocabulary/variantOf" : [ {
      "@id" : "http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=936"
    } ]
  }, {
    "@id" : "http://www.tkuhn.ch/bel2nanopub/RAQfV5-xLlpw3kxtvQ4VjUdtLbOMXTLLzcIv2KILNHN2Q#_2",
    "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ],
    "http://purl.obolibrary.org/obo/BFO_0000066" : [ {
      "@id" : "http://purl.bioontology.org/ontology/MSH/D001940"
    }, {
      "@id" : "http://purl.bioontology.org/ontology/MSH/D003106"
    }, {
      "@id" : "http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=9606"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ {
      "@id" : "http://purl.bioontology.org/ontology/MSH/D017209"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ {
      "@id" : "http://www.selventa.com/vocabulary/decreases"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ {
      "@id" : "http://www.tkuhn.ch/bel2nanopub/RAQfV5-xLlpw3kxtvQ4VjUdtLbOMXTLLzcIv2KILNHN2Q#_1"
    } ]
  }, {
    "@id" : "http://www.tkuhn.ch/bel2nanopub/RAQfV5-xLlpw3kxtvQ4VjUdtLbOMXTLLzcIv2KILNHN2Q#assertion",
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "p(HGNC:BAD,pmod(P,S)) -| bp(MESHPP:Apoptosis)"
    } ]
  } ],
  "@id" : "http://www.tkuhn.ch/bel2nanopub/RAQfV5-xLlpw3kxtvQ4VjUdtLbOMXTLLzcIv2KILNHN2Q#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel",
    "http://purl.org/dc/elements/1.1/description" : [ {
      "@value" : "Approximately 61,000 statements."
    } ],
    "http://purl.org/dc/elements/1.1/rights" : [ {
      "@value" : "Copyright (c) 2011-2012, Selventa. All rights reserved."
    } ],
    "http://purl.org/dc/elements/1.1/title" : [ {
      "@value" : "BEL Framework Large Corpus Document"
    } ],
    "http://purl.org/pav/authoredBy" : [ {
      "@id" : "http://www.tkuhn.ch/bel2nanopub/RAQfV5-xLlpw3kxtvQ4VjUdtLbOMXTLLzcIv2KILNHN2Q#_4"
    } ],
    "http://purl.org/pav/version" : [ {
      "@value" : "1.4"
    } ]
  }, {
    "@id" : "http://www.tkuhn.ch/bel2nanopub/RAQfV5-xLlpw3kxtvQ4VjUdtLbOMXTLLzcIv2KILNHN2Q#_3",
    "http://www.w3.org/ns/prov#value" : [ {
      "@value" : "STATs are important regulators of breast development and carcinogenesis. Constitutively elevated STAT DNA-binding activity is seen in primary breast tumor specimens from patients with advanced disease compared to adjacent nontumor tissues Constitutively active STAT3 mediates oncogenic transformation in immortalized fi- broblasts and induces tumor formation in nude mice, suggesting a pivotal role of STAT3 in transformation (48) Berclaz et al. found a very strong correlation between nuclear STAT3 andEGFRexpression in breast cancers cells. ProstaglandinHsynthetases (composed of Cox- 1 and Cox-2 isoenzymes) convert arachidonic acid into prostaglandins that are further modified to produce important signal molecules Induced Cox-2 expression is seen in almost all tumor sites. It was shown over a decade ago that both PGE1 and PGE2 enhance mitogenesis in mammary epithelial cells stimulated with EGF (165,166). In Hs578T breast cancer cells, Cox-2 expression is related to digestion of basement membrane, resulting in cellular invasiveness (167). Cox-2 expression is seen in the majority of HER2-overexpressing breast cancers, and in a small fraction of HER2-negative breast cancers as well (164) Posttranslational farnesylation is required for Ras to function in the inner membrane surface, a process catalyzed by farnesyl transferase. Substrates for this enzyme include all four Ras proteins as well as other non-Ras proteins (e.g., RhoB) that have the amino acid CAAX motif where X represents methionine or serine A direct role of Raf in the development of human cancers is well documented in literature (161). In MCF-7 cells, Raf-1 and A-Raf are upregulated after treatment with (-) estradiol, but not in ER-negative cells. Overexpression of constitutively active Raf-1 causes cell cycle progression and results in an increased proliferative response to (-) estradiol (273). Raf-1 protein is overexpressed in the cytosol fraction of human breast cancer tissues but not in normal mammary gland tissue ( Geldanamycin, herbimycin A, 17-allylaminogeldanamycin (17-AAG), radicicol, KF25706, and KF58333 represent a class of compounds that bind to heat-shock protein-90 (Hsp90) (Table II). They destabilize Hsp90-associating proteins including Raf- 1, ErbB2, Akt, p53, v-Src, Bcr-Abl, HIF-1a, ER, PR, and glucocorticoid receptors (277). Hence, geldanamycin and its analogs are not specific for any one target. Geldanamycin causes destabilization of Raf- 1 and loss of Raf-1-Ras association, the Raf-MEKMAPK signaling pathway (278,279). Geldanamycin increases the recruitment of chaperone-interacting protein (CHIP), which is known to efficiently ubiquitinate and down-regulate ErbB2 in COS7 cells (280). KF58333, an oxime derivative of radicicol, is a potent growth inhibitor of high- and low-Her2 expressing breast cell lines (212). 17-AAG, a geldanamycin analog, has less toxicity than its predecessor and is able to downregulate Akt expression, inhibit PI3K and Akt activity, suppress cyclin D expression, and ultimately inhibit growth of HER2-overexpressing breast cancer It has been shown that Akt has antiapoptosis effect by phosphorylating Bad and other death proteins (285-287). Akt"
    } ],
    "http://www.w3.org/ns/prov#wasQuotedFrom" : [ {
      "@id" : "http://www.ncbi.nlm.nih.gov/pubmed/14587863"
    } ]
  }, {
    "@id" : "http://www.tkuhn.ch/bel2nanopub/RAQfV5-xLlpw3kxtvQ4VjUdtLbOMXTLLzcIv2KILNHN2Q#_4",
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "Selventa"
    } ]
  }, {
    "@id" : "http://www.tkuhn.ch/bel2nanopub/RAQfV5-xLlpw3kxtvQ4VjUdtLbOMXTLLzcIv2KILNHN2Q#assertion",
    "http://www.w3.org/ns/prov#hadPrimarySource" : [ {
      "@id" : "http://www.ncbi.nlm.nih.gov/pubmed/14587863"
    } ],
    "http://www.w3.org/ns/prov#wasDerivedFrom" : [ {
      "@id" : "http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel"
    }, {
      "@id" : "http://www.tkuhn.ch/bel2nanopub/RAQfV5-xLlpw3kxtvQ4VjUdtLbOMXTLLzcIv2KILNHN2Q#_3"
    } ]
  } ],
  "@id" : "http://www.tkuhn.ch/bel2nanopub/RAQfV5-xLlpw3kxtvQ4VjUdtLbOMXTLLzcIv2KILNHN2Q#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://www.tkuhn.ch/bel2nanopub/RAQfV5-xLlpw3kxtvQ4VjUdtLbOMXTLLzcIv2KILNHN2Q",
    "http://purl.org/dc/terms/created" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2014-07-03T14:30:17.929+02:00"
    } ],
    "http://purl.org/pav/createdBy" : [ {
      "@id" : "http://orcid.org/0000-0001-6818-334X"
    }, {
      "@id" : "http://orcid.org/0000-0002-1267-0234"
    } ]
  } ],
  "@id" : "http://www.tkuhn.ch/bel2nanopub/RAQfV5-xLlpw3kxtvQ4VjUdtLbOMXTLLzcIv2KILNHN2Q#pubinfo"
} ]